ASH 2024: Breakthrough Insights on CAR T-Cell Therapy for Relapsed/Refractory ALL
home / peer-exchange / ash-2024-breakthrough-insights-on-car-t-cell-therapy-for-relapsed-refractory-all
Panelists discuss how recent advancements in CAR T-cell therapies, including the FDA approval of obe-cel and updates from the ZUMA-3 and FELIX trials, are reshaping the treatment landscape for relapsed/refractory ALL, with a focus on patient selection, bridging therapies, toxicity management, and health care resource utilization.
New content coming soon.
